
    
      TRIAL DRUG:

      GMRx2: Single pill combinations of telmisartan/amlodipine/indapamide Dose version 2:
      telmisartan 20mg/amlodipine 2.5mg/indapamide 1.25mg Dose version 3: telmisartan
      40mg/amlodipine 5 mg/indapamide 2.5mg INDICATION: Hypertension TRIAL DESIGN: International,
      multicenter, randomized, double-blind, active controlled, parallel-group.

      OBJECTIVES: To investigate the efficacy and safety of GMRx2 compared to dual combinations

      INTERVENTION:

      Single-Blind Active Run-In Period. Enrolled participants will be asked to discontinue their
      current BP-lowering drug(s) and undergo a single-blind active run-in period for 4 weeks with
      GMRx2 dose version 2. Participants will be advised to take the capsule once daily in the
      morning at the same time (Â± 2 hours) before home BP measurement is performed.

      Double-Blind Treatment Period. Participants still eligible after the run-in period will be
      allocated in a double-blind fashion to one of the following 4 randomized groups: GMRx2 dose
      version 2, or telmisartan20mg+amlodipine2.5mg, or telmisartan 20mg+indapamide 1.25mg, or
      amlodipine2.5mg+indapamide 1.25mg. At week 6 all doses will be doubled.
    
  